Anifrolumab bei systemischem Lupus erythematodes

Yurkovich M et al (2014) Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res 66:608–616
Article Google Scholar
Mathian A et al (2015) Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs 75:835–846
Article CAS PubMed Google Scholar
Kalunian KC et al (2016) A phase II study of efficacy and sfafety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 75:196–202
Article PubMed Google Scholar
Khamashta M et al (2016) Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study. Ann Rheum Dis 75:1909–1916
Article CAS PubMed PubMed Central Google Scholar
Navarra SV et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet 377:721–731
Article CAS PubMed Google Scholar

Author information

Medizinische Klinik und Poliklinik III, Bereich Rheumatologie, Universitätsklinikum TU Dresden, Dresden, Deutschland
A. Erler

Authors

A. Erler
View author publications
You can also search for this author in PubMed Google Scholar

Correspondence to A. Erler.

A. Erler gibt an, dass kein Interessenkonflikt besteht.

C. Fiehn, Baden Baden

B. Hellmich, Kirchheim-Teck

I. Kötter, Hamburg

K. Krüger, München

Erler, A. Anifrolumab bei systemischem Lupus erythematodes. Z Rheumatol 77, 175–176 (2018). https://doi.org/10.1007/s00393-018-0420-y

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.